Jon Weidanz

This inventor holds 6 USPTO granted patents and 8 published patent applications. Top assignees: Abexxa Biologics, Inc., Boehringer Ingelheim International Gmbh, Boehringer Ingelheim Pharmaceuticals, Inc.. Active years: 2021-2024.

USPTO Granted Patents = 6 (Patent Applications = 8)

% Patents Active = 100.0

Average Co-Inventor Count = 2.2

ph-index = 2

Forward Citations = 11(Granted Patents)

Company Filing History:

2 out of 2

Abexxa Biologics, Inc.

patents

2 out of 1,561

Boehringer Ingelheim International Gmbh

patents

1 out of 278

Boehringer Ingelheim Pharmaceuticals, Inc.

patents

4. 1 out of 5,633

The University of Texas System

patents

Years Active: 2021-2024

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12173072 - Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use (2024-12-24),

2. 11976120 - Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use (2024-05-07),

3. 11971405 - Nanosensors and methods of making and using nanosensors (2024-04-30),

4. 11359023 - Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use (2022-06-14),

5. 10981997 - Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use (2021-04-20),

6. 10981996 - Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use (2021-04-20),

Title: Jon Weidanz: Innovator in Antibody Development

Introduction

Jon Weidanz is a prominent inventor based in Arlington, TX (US), known for his significant contributions to the field of biotechnology. He holds a total of 6 patents, focusing primarily on innovative antibody technologies. His work has the potential to impact therapeutic approaches in various medical applications.

Latest Patents

Weidanz's latest patents include groundbreaking developments in antibodies that target a complex comprising non-classical HLA-I and neoantigens. These antibodies are designed to selectively bind to complexes that include non-classical HLA-I, such as HLA-E, and neoantigens characterized by variable heavy chain domains (VH), variable light chain domains (VL), and complementarity determining regions (CDRs). The methods and uses of these antibodies are also disclosed, showcasing their potential in advancing medical treatments.

Career Highlights

Throughout his career, Jon Weidanz has worked with notable companies in the biotechnology sector, including Boehringer Ingelheim International GmbH and Abexxa Biologics, Inc. His experience in these organizations has contributed to his expertise in antibody development and innovation.

Collaborations

Weidanz has collaborated with several talented individuals in his field, including Katherine Upchurch-Ange and Sai Santosh Sasank Peri. These collaborations have further enriched his research and development efforts.

Conclusion

Jon Weidanz stands out as an influential inventor in the biotechnology industry, particularly in the realm of antibody development. His innovative patents and collaborations reflect his commitment to advancing medical science and improving therapeutic options.